{{Drugbox
| Watchedfields = changed
| verifiedrevid = 462100725
| IUPAC_name = (±)-5-(4-chlorophenyl)-3,5-dihydro-2''H''-imidazo[2,1-''a'']isoindol-5-ol
| image = Mazindol.svg
| width = 200px
| image2 = Mazindol3Dan.gif
| width2 = 250px

<!--Clinical data-->
| tradename = Mazanor, Sanorex
| Drugs.com = {{drugs.com|CONS|mazindol}}
| legal_AU = S4
| legal_CA = Schedule IV
| legal_US = Schedule IV
| legal_DE = Anlage II
| legal_status = [[Schedule IV controlled substance|Schedule IV]] (International){{how|date=February 2017}}
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 93%
| metabolism = [[Liver|Hepatic]]
| elimination_half-life = 10–13 hours
| excretion = [[Kidney|Renal]]

<!--Identifiers-->
| IUPHAR_ligand = 4797
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 22232-71-9
| ATC_prefix = A08
| ATC_suffix = AA05
| ATC_supplemental = 
| PubChem = 4020
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00579
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3880
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = C56709M5NH
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00367
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 781

<!--Chemical data-->
| C=16 | H=13 | Cl=1 | N=2 | O=1
| molecular_weight = 284.74 g/mol
| SMILES = ClC1=CC=C(C2(C3=CC=CC=C3C4=NCCN42)O)C=C1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZPXSCAKFGYXMGA-UHFFFAOYSA-N
| chirality = [[Racemic mixture]]
}}

'''Mazindol''' (brand names '''Mazanor''', '''Sanorex''') is a [[stimulant]] [[drug]] which is used as an [[appetite suppressant]].<ref>{{cite journal |author1=Carruba, Michele O. |author2=Zambotti, Fernanda |author3=Vicentini, Lucia |author4=Picotti, Giovanni B. |author5=Mantegazza, Paolo | title = Pharmacology and biochemical profile of a new anorectic drug: mazindol | journal = Cent. Mech. Anorectic Drugs | year = 1978 | pages = 145–64}}</ref> It was developed by [[Sandoz Laboratories|Sandoz-Wander]] in the 1960s.<ref>US Patent 3597445 - 1H-Isoindole Intermediates</ref>

==Medical uses==
Mazindol is used in short-term (i.e., a few weeks) treatment of exogenous [[obesity]], in combination with a regimen of weight reduction based on [[caloric restriction]], [[exercise]], and [[behavior modification]] in patients with a [[body mass index]] of 30&nbsp;kg of body weight per height in meters squared (kg/m²), or in patients with a body mass index of 27&nbsp;kg/m2 in the presence of risk factors such as [[hypertension]], [[diabetes]], or [[hyperlipidemia]]. Mazindol is not currently available as a commercially marketed and FDA regulated prescription agent for the treatment of obesity.

==Pharmacology==
Mazindol is a [[sympathomimetic amine]], which is similar to [[amphetamine]]. It stimulates the [[central nervous system]], which increases heart rate and [[blood pressure]], and decreases [[appetite]]. Sympathomimetic anoretics (appetite suppressants) are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks of treatment. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.

Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Like other sympathomimetic appetite suppressants, mazindol is thought to act as a [[Norepinephrine reuptake inhibitor|reuptake inhibitor]] of [[norepinephrine]]. In addition, it inhibits [[dopamine]] and [[serotonin]] [[reuptake]]. The recommended dosage is 2&nbsp;mg per day for 90 days in patients 40&nbsp;kg overweight and under; 4&nbsp;mg a day in patients more than 50&nbsp;kg overweight; separated into two doses separated by a 12-hour window between each 2&nbsp;mg dose.

==Overdose==
Symptoms of a mazindol overdose include: [[Psychomotor agitation|restlessness]], [[tremor]], [[rapid breathing]], [[confusion]], [[hallucination]]s, [[panic]], [[aggressiveness]], [[nausea]], [[vomiting]], [[diarrhea]], an [[irregular heartbeat]], and [[seizure]]s.

==Chemistry==

===Analogues===
From considering the attached [[structure activity relationship|QSAR]] table we can make the apparent observations:<ref>{{Cite journal
| pmid = 12213054
| year = 2002
| last1 = Houlihan | first1 = W. J.
| last2 = Ahmad
| last3 = Koletar
| last4 = Kelly
| last5 = Brand
| last6 = Kopajtic
| title = Benzo- and cyclohexanomazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter
| volume = 45
| issue = 19
| pages = 4110–4118
| journal = [[Journal of Medicinal Chemistry]]
| doi = 10.1021/jm010301z | first2 = U. F. | first3 = J. | first4 = L. | first5 = L. | first6 = T. A.
}}{{Cite journal
| pmid = 12213053
| year = 2002
| last1 = Houlihan | first1 = W. J.
| last2 = Kelly
| last3 = Pankuch
| last4 = Koletar
| last5 = Brand
| last6 = Janowsky
| last7 = Kopajtic
| title = Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter
| volume = 45
| issue = 19
| pages = 4097–4109
| journal = [[Journal of Medicinal Chemistry]]
| doi = 10.1021/jm010302r | first2 = L. | first3 = J. | first4 = J. | first5 = L. | first6 = A. | first7 = T. A.
}}</ref>
# Desoxylation of the tertiary alcohol in mazindol improves DAT and SERT binding. The compound now behaves as a functional SNDRI instead of predominantly a [[noradrenaline reuptake inhibitor]].
# Removal of the ''p''-chloro atom in mazindol means that the compound now only behaves as a noradrenaline reuptake inhibitor.
# Changing the size of the [[2-Imidazoline|imidazoline]] type ring system in mazindol to the corresponding six-membered homolog increases potency of the resultant compound at the DAT by approximately ten-fold.
[[File:Mazindol analogs 2.svg|left|250px]]
{| class="wikitable"
|-
!n
!R
!R'
!R"
!hSERT
!hNET
!hDAT
|-
|1||Cl||H||OH||94||4.9||43
|-
|1||Cl||H||H||15||6.9||6.0
|-
|1||H||H||OH||2140||2.8||730
|-
|1||colspan=2|-C4H4-||OH||1.8||4.5||66
|-
|2||Cl||H||OH||53||4.9||3.7
|-
|2||OH||H||OH||60||1.9||59.0
|-
|2||OMe||H||OH||94||4.1||30.4
|-
|2||colspan=2|-OCH2O-||OH||83||0.62||2.21
|-
|}

To make the six membered (so-called homomazindol) analog, one can simply substitute 1,2-diaminoethane with 1,3-diaminopropane. Importantly, another procedure was also published.

Given the data in the above table, one might also be interested in making the desoxy-mazindol analog. The synthesis for this is facile. Although "mazindane" is relatively stable in air, it is readily oxidized to mazindol upon contact with monoamine oxidaze enzymes present at the DAT.

{| class="wikitable sortable"
|+Mazindol analogs with phenyl ring substitutions{{efn|<ref name=Singh>[https://www.erowid.org/archive/rhodium/pdf/cocaineanalogs.pdf Chemistry, Design, and Structure-Activity Relationship of Cocaine Antagonists. Satendra Singh et al. Chem. Rev. 2000, 100. 925-1024. PubMed; Chemical Reviews (Impact Factor: 45.66). 04/2000; 100(3):925-1024 American Chemical Society; 2000) ChemInform; May, 16th 2000, Volume 31, Issue 20.], {{ISSN|0009-2665}}, {{doi|10.1002/chin.200020238}}. [https://www.scribd.com/doc/77191354/Satendra-Singh-Chemistry-Design-and-Structure-Activity-Relationship-of-Cocaine-Antagonists Mirror hotlink.]</ref> ←Page #1,012 (88th page of article) Figure 57 & Page #1,013 (89th page of article) Table 51}}
! Compound
! S. Singh's<br />alphanumeric<br />assignation<br />(name)
! ''R''
! ''R′''
! ''R′′''
! IC<sub>50</sub> (nM)<br />(Inhibition of [<sup>3</sup>H]WIN 35428 binding)
! IC<sub>50</sub> (nM)<br />(Inhibition of [<sup>3</sup>H]DA uptake)
! Selectivity<br />uptake/binding
|-
| || ([[cocaine]]) || || || ||89.1 ± 8||208 ± 12||2.3
|-
|rowspan=18|
|-
| (mazindol) || H || H || 4′-Cl ||8.1 ± 1.2||8.4 ± 1.3||1.0
|-
| 384a || H || H || H ||66.0 ± 8.9||124 ± 37||1.9
|-
| 384b || H || H || 4′-F ||13.3 ± 1.8||25.4 ± 2.7||1.9
|-
| 384c || H || 7-F || H ||29.7 ± 7.0||78 ± 46||2.6
|-
| 384d || H || H || 2′-Cl ||294 ± 6||770 ± 159||2.6
|-
| 384e || H || H || 3′-Cl ||4.3 ± 0.4||9.2 ± 5.3||2.1
|-
| 384f || CH<sub>3</sub> || H || 4′-Cl ||50.4 ± 5.5||106 ± 5.6||2.1
|-
| 384g || H || 6-Cl || H ||57.2 ± 8.3||58 ± 6.4||1.0
|-
| 384h || H || 7-Cl || H ||85.4 ± 14|| 55.17 ||0.6
|-
| 384i || H || 7-F || 4′-Cl ||6.5 ± 1.2||15 ± 9||2.3
|-
| 384j || H || 7-Cl || 4′-F ||52.8 ± 8.7||53 ± 18||1.0
|-
| 384k || H || H || 2′,4′-Cl<sub>2</sub> ||76.5 ± 1.11||92 ± 19||1.2
|-
| 384l || H || H || 3′,4′-Cl<sub>2</sub> ||2.5 ± 0.5||1.4 ± 1.6||0.6
|-
| 384m || H || 7,8-Cl<sub>2</sub> || 4′-Cl ||13.6 ± 1.5|| ||
|-
| 384n || H || H || 2′-Br ||1340 ± 179|| ||
|-
| 384o || H || H || 4′-Br ||2.6 ± 1.5||8.6 ± 3.5||3.3
|-
| 384p || H || H || 4′-I ||17.2 ± 0.9||14 ± 6.4||0.8
|}

{| class="wikitable sortable"
|+Mazindol Ring A homologues{{efn|<ref name=Singh /> ←Page #1,012 (88th page of article) Figure 58 & Page #1,014 (90th page of article) Table 52}}
! Compound
! S. Singh's<br />alphanumeric<br />assignation<br />(name)
! ''R''
! ''R′''
! IC<sub>50</sub> (nM)<br />(Inhibition of [<sup>3</sup>H]WIN 35428 binding)
! IC<sub>50</sub> (nM)<br />(Inhibition of [<sup>3</sup>H]DA uptake)
! Selectivity<br />uptake/binding
|-
|rowspan=8|
|-
| 388a || H || H ||5.8 ± 1.6||18 ± 11||3.1
|-
| 388b || H || 2′-F ||23.2 ± 1.7||89 ± 2.8||3.8
|-
| 388c || H || 3′-F ||2.0 ± 0.02||3.1 ± 1.8||1.6
|-
| 388d || H || 4′-F ||3.2 ± 1.7||8.5 ± 4.9||0.4
|-
| 388e || H || 3′-Cl ||1.0 ± 0.2||1.3 ± 0.14||1.3
|-
| 388f || H || 4′-Cl ||1.7 ± 0.2||1.4 ± 0.35||0.8
|-
| 388g || CH<sub>3</sub> || 4′-Cl ||6.3 ± 4.5||1.7 ± 1.6||0.3
|-
|rowspan=4|
|-
| 389a || H || ||5.9 ± 0.1||11 ± 3.2||2.0
|-
| 389b || 4′-Cl || ||1.5 ± 0.1||3.4 ± 2.3||2.3
|-
| 389c || 3′,4′-Cl<sub>2</sub> || ||1.7 ± 0.1||0.26 ± 0.16||0.2
|}

See also: [[SNDRI]] for context.

===Synthesis===
[[File:Mazindol synthesis.svg|thumb|center|1000px|Mazindol synthesis:<ref>{{cite journal|doi=10.1021/jm00236a014|pmid=804553|title=5-Aryl-2,3-dihydro-5H-imidazo[2,1-a]isoindol-5-ols. Novel class of anorectic agents|journal=Journal of Medicinal Chemistry|volume=18|issue=2|pages=177|year=1975|last1=Aeberli|first1=Paul|last2=Eden|first2=Phillip|last3=Gogerty|first3=John H.|last4=Houlihan|first4=William J.|last5=Penberthy|first5=Chris}}</ref><ref>W. J. Houlihan, {{Cite patent|DE|1814540}} C.A. 71, 81368s (1969).</ref><ref>W. J. Houlihan, M. K. Eberle, {{Cite patent|DE|1930488}}; eidem, {{US patent|3597445}} (1969, 1970, 1970 all to [[Sandoz]]).</ref><ref>T. S. Sulkowski, {{US patent|3763178}} (1973 to [[American Home Products]]).</ref>]]
Preparation starts by reaction of a substituted benzoylbenzoic acid ('''1''') with [[ethylenediamine]] The product '''3''' can be rationalized as being an [[aminal]] from the initially formed monoamide '''2'''. This is then subjected to reduction with [[LiAlH4]] and-without isolation-air oxidation. Reduction probably proceeds to the mixed aminal/carbinolamine '''4'''; such a product would be expected to be in equilibrium with the alternate aminal '''5'''. The latter would be expected to predominate because of the greater stability of aldehyde aminals over the corresponding ketone derivatives. Air oxidation of the tetrahydroimidazole to the imidazoline will then remove '''5''' from the equilibrium. There is thus obtained the anorectic agent mazindol ('''6''').

==Research==
As of 2016 mazindol was being studied in clinical trials for [[attention-deficit hyperactivity disorder]].<ref>{{cite journal|last1=Mattingly|first1=GW|last2=Anderson|first2=RH|title=Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.|journal=CNS Spectrums|date=December 2016|volume=21|issue=S1|pages=45–59|doi=10.1017/S1092852916000808|pmid=28044946}}</ref>

==See also==
* [[Ciclazindol]]
* [[Setazindol]]
* [[Trazium]]

==References==
{{Reflist}}
{{Notelist}}


{{Stimulants}}
{{Anorectics}}
{{Monoamine reuptake inhibitors}}
{{Tricyclics}}

[[Category:Alcohols]]
[[Category:Chloroarenes]]
[[Category:Imidazolines]]
[[Category:Serotonin-norepinephrine-dopamine reuptake inhibitors]]
[[Category:Stimulants]]
[[Category:Sympathomimetic amines]]